Alterity Therapeutics Limited, a biotechnology company focusing on treatments for neurodegenerative diseases, has announced a change in its share registry service provider. Effective from October 7, 2024, the company will transition from Computershare Investor Services Pty Ltd to Automic Pty Ltd. This change aims to enhance shareholder experience through Automic's secure online investor portal, which offers services such as updating personal details, viewing balances, and transaction history. Shareholders are encouraged to register with Automic's portal to manage their holdings and can contact Automic for support regarding their Alterity holdings. The announcement, authorized by CEO David Stamler, also includes forward-looking statements about the company's drug development program and the progress of clinical trials, specifically mentioning ATH434, a drug compound in development.

Alterity Therapeutics Limited, a biotechnology company focusing on treatments for neurodegenerative diseases, has announced a change in its share registry service provider. Effective from October 7, 2024, the company will transition from Computershare Investor Services Pty Ltd to Automic Pty Ltd. This change aims to enhance shareholder experience through Automic's secure online investor portal, which offers services such as updating personal details, viewing balances, and transaction history. Shareholders are encouraged to register with Automic's portal to manage their holdings and can contact Automic for support regarding their Alterity holdings. The announcement, authorized by CEO David Stamler, also includes forward-looking statements about the company's drug development program and the progress of clinical trials, specifically mentioning ATH434, a drug compound in development.